COCHLEAR LIMITED (COH)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

COH - COCHLEAR LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Cochlear is a medical device company that designs, manufactures and supplies hearing implants to the global market. Formed in 1981 with finance from the Australian government, it became a listed entity in 1995, and has grown to become the global leader in its field.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$212.00

05 Dec
2022

-3.480

OPEN

$215.25

-1.61%

HIGH

$215.25

124,476

LOW

$210.01

TARGET
$217.783 2.7% upside
Franking for last dividend paid out: 40%
OTHER COMPANIES IN THE SAME SECTOR
ELX . PGC . AHZ . FPH . IPD . LHC . NAN . RMD . SOM . HLA . MX1 . CAT . VHT . ONE . IDX . PME . CSX . 4DX . BRN . EMV . UBI . LDX . RAP . RVA . MEB . IME . PCK . CMP . CYC . IMR . VTI . OVN . EYE . CGS . CU6 . TRJ . EBR . PEB . AT1 . CBL .
FNARENA'S MARKET CONSENSUS FORECASTS
COH: 1
Title FY21
Actual
FY22
Actual
FY23
Forecast
FY24
Forecast
EPS (cps) xxx 439.6 456.4 xxx
DPS (cps) xxx 300.0 321.7 xxx
EPS Growth xxx - 11.5% 3.8% xxx
DPS Growth xxx 17.6% 7.2% xxx
PE Ratio xxx N/A 46.5 xxx
Dividend Yield xxx N/A 1.5% xxx
Div Pay Ratio(%) xxx 68.3% 70.5% xxx

Dividend yield today if purchased 3 years ago: 1.30%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

1.39

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 21/09 - ex-div 145c (franking 40%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2022 FactSet UK Limited. All rights reserved
Title 201720182019202020212022
EPS Basic xxxxxxxxxxxxxxx439.6
DPS All xxxxxxxxxxxxxxx300.0
Sales/Revenue xxxxxxxxxxxxxxx1,641.1 M
Book Value Per Share xxxxxxxxxxxxxxx2,562.8
Net Operating Cash Flow xxxxxxxxxxxxxxx376.5 M
Net Profit Margin xxxxxxxxxxxxxxx17.62 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201720182019202020212022
Return on Capital Employed xxxxxxxxxxxxxxx17.07 %
Return on Invested Capital xxxxxxxxxxxxxxx15.24 %
Return on Assets xxxxxxxxxxxxxxx11.79 %
Return on Equity xxxxxxxxxxxxxxx17.07 %
Return on Total Capital xxxxxxxxxxxxxxx18.52 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx138.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

5

xxxxxxxxx xx xxxxxxxxxxxx xxxx xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxxxx xx xxxxxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Credit Suisse

22/08/2022

3

Neutral

$232.00

9.43%

Cochlear reported 10% year-on-year net profit growth in the second half to $277m, within guidance range but a -3% miss to consensus estimates as noted by Credit Suisse. 

The broker notes despite market improvement, higher costs saw net profit decline half-on half to $120m, from $158m in the first half. The company is guiding to 5-10% net profit growth in FY23, including a $10m year-on-year step up in its cloud IT investment to $25m. 

Credit Suisse anticipates a weaker first half in FY23 as hospital staffing shortages continue to impact. The Neutral rating and target price of $232 are retained.

FORECAST
Credit Suisse forecasts a full year FY23 dividend of 318.00 cents and EPS of 454.00 cents.
Credit Suisse forecasts a full year FY24 dividend of 365.00 cents and EPS of 522.00 cents.

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

COH STOCK CHART